Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Pötzsch

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|April 30, 2013
[Anticoagulation]B Pötzsch
The New England Journal of Medicine|September 8, 2001
ThrombophiliaB Pötzsch, K Madlener
Hamostaseologie|January 31, 2006
[The management of patients with heparin-induced thrombocytopenia]B Pötzsch, K Madlener
Hamostaseologie|February 12, 2011
Haemostasis management of massive bleedingB Pötzsch, V Ivaskevicius
Hamostaseologie|August 24, 2002
[APC (activated protein C) resistance]B Pötzsch, I Witt
Histology and Histopathology|January 1, 1995
Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectinK T Preissner, B Pötzsch
The New England Journal of Medicine|August 19, 2000
Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopeniaB Pötzsch, W P Klövekorn, K Madlener
Hamostaseologie|November 9, 2011
Aptamer-based modulation of blood coagulationG Mayer, F Rohrbach, B Pötzsch, et al.
Journal of Thrombosis and Haemostasis : JTH|October 2, 2008
Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinaseJ Müller, D Freitag, G Mayer, et al.
Hamostaseologie|February 19, 2008
[New insight in therapeutic anticoagulation by Coumarin derivatives]J Oldenburg, H Seidel, B Pötzsch, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|April 30, 2013
[Anticoagulation]B Pötzsch
The New England Journal of Medicine|September 8, 2001
ThrombophiliaB Pötzsch, K Madlener
Hamostaseologie|January 31, 2006
[The management of patients with heparin-induced thrombocytopenia]B Pötzsch, K Madlener
Hamostaseologie|February 12, 2011
Haemostasis management of massive bleedingB Pötzsch, V Ivaskevicius
Hamostaseologie|August 24, 2002
[APC (activated protein C) resistance]B Pötzsch, I Witt
Histology and Histopathology|January 1, 1995
Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectinK T Preissner, B Pötzsch
The New England Journal of Medicine|August 19, 2000
Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopeniaB Pötzsch, W P Klövekorn, K Madlener
Hamostaseologie|November 9, 2011
Aptamer-based modulation of blood coagulationG Mayer, F Rohrbach, B Pötzsch, et al.
Journal of Thrombosis and Haemostasis : JTH|October 2, 2008
Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinaseJ Müller, D Freitag, G Mayer, et al.
Hamostaseologie|February 19, 2008
[New insight in therapeutic anticoagulation by Coumarin derivatives]J Oldenburg, H Seidel, B Pötzsch, et al.
Pageof 5